{"id":"talazoparib-with-enzalutamide","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of hypomagnesemia"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of QT interval prolongation"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac arrhythmias"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac arrest"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac ischemia"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac failure"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac hypertrophy"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac valve disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"},{"drug":"Enzalutamide","action":"Monitor","effect":"Increased risk of cardiac conduction disorders"}],"commonSideEffects":[],"contraindications":["None."],"specialPopulations":{"Pregnancy":"TALZENNA can cause fetal harm when administered to pregnant women. Advise females to inform their healthcare provider if they are pregnant or become pregnant during treatment with TALZENNA. Advise females of reproductive potential to use effective contraception during treatment with TALZENNA. The effects of the drug on the breastfed child are unknown. Because of the potential for serious adverse reactions in a breastfed child from talazoparib, advise lactating women not to breastfeed during treatment with TALZENNA and for 1 month after the last dose.","Geriatric use":"No specific guidance is provided for geriatric use.","Paediatric use":"The safety and effectiveness of TALZENNA have not been established in pediatric patients.","Renal impairment":"Reduce the recommended dosage of TALZENNA in patients with moderate (CLcr 30 – 59 mL/min) and severe renal impairment (CLcr < 30 mL/min).","Hepatic impairment":"No dosage modification is recommended for patients with hepatic impairment."}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=talazoparib-with-enzalutamide","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:51:45.505045+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:51:52.388226+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:51:45.577814+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=talazoparib-with-enzalutamide","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:51:52.654311+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Androgen Receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:51:54.100684+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1082407/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:51:53.766714+00:00"}},"allNames":"talazoparib with enzalutamide","offLabel":[],"timeline":[{"date":"2023-01-01","type":"Clinical","milestone":"Phase 3 trial initiation","regulator":"FDA"},{"date":"2024-06-01","type":"Regulatory","milestone":"NDA submission","regulator":"FDA"},{"date":"2025-01-01","type":"Regulatory","milestone":"Potential FDA approval","regulator":"FDA"}],"_dailymed":null,"aiSummary":"Talazoparib in combination with enzalutamide is an investigational therapy being developed by Pfizer Inc. for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The combination leverages the PARP inhibition properties of talazoparib and the androgen receptor signaling inhibitor properties of enzalutamide to enhance antitumor activity. While there is no FDA-approved label for this combination, clinical trials have shown promising results in extending progression-free survival and improving overall outcomes in patients with mCRPC. However, the combination therapy also comes with a range of side effects that need to be managed carefully. Pfizer is actively pursuing regulatory approval for this combination, and it has the potential to become a significant addition to the treatment landscape for mCRPC.","brandName":"Talazoparib with enzalutamide","ecosystem":[],"isGeneric":true,"mechanism":{"target":"PARP enzymes and androgen receptor","novelty":"The combination of a PARP inhibitor with an androgen receptor inhibitor represents a novel approach to treating mCRPC by targeting multiple pathways involved in tumor growth and survival.","modality":"Small molecule combination therapy","drugClass":"PARP inhibitor and androgen receptor inhibitor","explanation":"","oneSentence":"","technicalDetail":"Talazoparib traps PARP on damaged DNA, preventing the repair of single-strand breaks and leading to double-strand breaks, which are lethal to cancer cells. Enzalutamide binds to the androgen receptor, preventing its translocation to the nucleus and subsequent transcriptional activation of androgen-responsive genes."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:39.783Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"7%","launchDate":"Not yet launched","revenueYear":2025,"annualCostUS":"$80,000/yr","annualRevenue":2194,"genericStatus":"Generic — off-patent","revenueSource":"SEC 8-K Pfizer (2026-02-03)","currentRevenue":"$21.2B","revenueCurrency":"USD","patientPopulation":"Patients with metastatic castration-resistant prostate cancer (mCRPC)","peakSalesEstimate":"$21.2B","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:46:15.552584","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=talazoparib-with-enzalutamide","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=talazoparib-with-enzalutamide","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:51:55.401276+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Abiraterone acetate","company":"Bayer","advantage":"Competes with talazoparib plus enzalutamide in the first-line mCRPC setting with favorable results"},{"name":"Docetaxel","company":"Sanofi","advantage":"Competes with talazoparib plus enzalutamide in the first-line mCRPC setting with favorable results"},{"name":"Olaparib","company":"Lynparza","advantage":"Competes with talazoparib plus enzalutamide by providing additional benefit in clinical endpoints when combined with abiraterone acetate"},{"name":"Niraparib","company":"Zejula","advantage":"Competes with talazoparib plus enzalutamide by providing additional benefit in clinical endpoints when combined with abiraterone acetate"}],"genericName":"talazoparib-with-enzalutamide","indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer (mCRPC) with BRCA1, BRCA2, or ATM gene mutations","regulator":"FDA"}],"offLabel":[],"pipeline":["Metastatic castration-resistant prostate cancer (mCRPC)"]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07477756","phase":"","title":"A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-09-04","conditions":"Prostate Cancer","enrollment":1247},{"nctId":"NCT03395197","phase":"PHASE3","title":"Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2017-12-18","conditions":"mCRPC","enrollment":1054},{"nctId":"NCT04821622","phase":"PHASE3","title":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-05-12","conditions":"Prostate Cancer","enrollment":599},{"nctId":"NCT05873192","phase":"PHASE2","title":"Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-06-03","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT06844383","phase":"PHASE2","title":"A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate","status":"RECRUITING","sponsor":"Prostate Cancer Clinical Trials Consortium","startDate":"2025-10","conditions":"Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)","enrollment":126},{"nctId":"NCT06168487","phase":"PHASE1","title":"Telmisartan in Prostate Cancer","status":"RECRUITING","sponsor":"Tyler J Curiel","startDate":"2024-04-22","conditions":"Prostate Cancer","enrollment":36},{"nctId":"NCT04332744","phase":"PHASE2","title":"Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-09-02","conditions":"Metastatic Prostate Cancer","enrollment":54},{"nctId":"NCT06582628","phase":"PHASE2","title":"Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)","status":"RECRUITING","sponsor":"Fundacion Oncosur","startDate":"2024-07-05","conditions":"Metastatic Prostate Cancer","enrollment":78},{"nctId":"NCT06585007","phase":"PHASE3","title":"Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2023-12-19","conditions":"Castration-resistant Prostate Cancer, Oligoprogressive","enrollment":246},{"nctId":"NCT03148795","phase":"PHASE2","title":"A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-07-04","conditions":"Prostate Cancer","enrollment":128},{"nctId":"NCT05406999","phase":"PHASE2","title":"Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2020-02-01","conditions":"Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer","enrollment":900},{"nctId":"NCT04052204","phase":"PHASE1, PHASE2","title":"Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2019-12-30","conditions":"Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":3}],"_emaApprovals":[{"date":"","name":"Talazoparib with enzalutamide","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":true,"chemblId":"CHEMBL1082407","moleculeType":"Small molecule","molecularWeight":"464.44"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL1082407"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-01 10:46:15.582442+00","biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule combination therapy","firstApprovalDate":"Not yet launched","enrichmentLevel":3,"visitCount":4,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:51:55.401276+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}